[go: up one dir, main page]

ID24929A - Turunan 2-aril-8-oksodihidropurin, proses pembuatannya, komposisi farmasinya yang mengandungnya, dan senyawa antaranya - Google Patents

Turunan 2-aril-8-oksodihidropurin, proses pembuatannya, komposisi farmasinya yang mengandungnya, dan senyawa antaranya

Info

Publication number
ID24929A
ID24929A IDW20000990A ID20000990A ID24929A ID 24929 A ID24929 A ID 24929A ID W20000990 A IDW20000990 A ID W20000990A ID 20000990 A ID20000990 A ID 20000990A ID 24929 A ID24929 A ID 24929A
Authority
ID
Indonesia
Prior art keywords
oxyodihydrropurin
durunan
aril
pharmacy
compound
Prior art date
Application number
IDW20000990A
Other languages
English (en)
Inventor
Teruya Murata
Kaoru Masumoto
Katsunori Kondo
Kiyoshi Furukawa
Makoto Oka
Original Assignee
Dainippon Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dainippon Pharmaceutical Co filed Critical Dainippon Pharmaceutical Co
Publication of ID24929A publication Critical patent/ID24929A/id

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IDW20000990A 1997-12-03 1998-11-26 Turunan 2-aril-8-oksodihidropurin, proses pembuatannya, komposisi farmasinya yang mengandungnya, dan senyawa antaranya ID24929A (id)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP35000097 1997-12-03

Publications (1)

Publication Number Publication Date
ID24929A true ID24929A (id) 2000-08-31

Family

ID=18407561

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW20000990A ID24929A (id) 1997-12-03 1998-11-26 Turunan 2-aril-8-oksodihidropurin, proses pembuatannya, komposisi farmasinya yang mengandungnya, dan senyawa antaranya

Country Status (26)

Country Link
US (1) US6372740B1 (id)
EP (1) EP1036794B1 (id)
JP (1) JP3815966B2 (id)
KR (1) KR100494347B1 (id)
CN (1) CN1146566C (id)
AR (1) AR017796A1 (id)
AT (1) ATE248169T1 (id)
AU (1) AU744014B2 (id)
BR (1) BR9815140A (id)
CA (1) CA2312885C (id)
DE (1) DE69817611T2 (id)
DK (1) DK1036794T3 (id)
ES (1) ES2205574T3 (id)
HU (1) HUP0004422A3 (id)
ID (1) ID24929A (id)
IL (1) IL135920A0 (id)
NO (1) NO20002835L (id)
NZ (1) NZ504457A (id)
PL (1) PL191489B1 (id)
PT (1) PT1036794E (id)
RU (1) RU2223272C2 (id)
SK (1) SK285703B6 (id)
TR (1) TR200001600T2 (id)
TW (1) TW502034B (id)
WO (1) WO1999028320A1 (id)
ZA (1) ZA9810490B (id)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003146987A (ja) * 1999-05-31 2003-05-21 Dainippon Pharmaceut Co Ltd ２−アリールプリン−９−アセトアミド誘導体
GB9913932D0 (en) 1999-06-15 1999-08-18 Pfizer Ltd Purine derivatives
EP1219608A4 (en) * 1999-09-27 2003-01-08 Ono Pharmaceutical Co PYRIMID DERIVATIVES, METHOD FOR PRODUCING THE DERIVATIVES AND MEDICINES CONTAINING IT AS THE ACTIVE COMPONENT
PL363870A1 (en) * 2000-07-31 2004-11-29 Dainippon Pharmaceutical Co, Ltd. Dementia remedies containing 2-aryl-8-oxodihydropurine derivatives as the active ingredient
EP1663994B1 (en) * 2003-08-05 2012-03-07 Vertex Pharmaceuticals Incorporated Tetrahydroquinazoline compounds as inhibitors of voltage-gated ion channels
US20070191447A1 (en) * 2004-02-23 2007-08-16 Toru Kodo Novel heterocyclic compound
EP1734820A4 (en) * 2004-04-16 2008-01-23 Neurogen Corp Imidazopyrrazine, imidazopyridine, and imidazo-pyrimidine as CRF1 receptor ligands
FR2870239B1 (fr) 2004-05-11 2006-06-16 Sanofi Synthelabo Derives de carbamate de 2h- ou 3h-benzo[e]indazol-1-yle, leur preparation et leur application en therapeutique.
US7884109B2 (en) * 2005-04-05 2011-02-08 Wyeth Llc Purine and imidazopyridine derivatives for immunosuppression
KR20080013886A (ko) * 2005-04-05 2008-02-13 파마코페이아, 인코포레이티드 면역억제용 퓨린 및 이미다조피리딘 유도체
GB0507298D0 (en) 2005-04-11 2005-05-18 Novartis Ag Organic compounds
US20070225304A1 (en) * 2005-09-06 2007-09-27 Pharmacopeia Drug Discovery, Inc. Aminopurine derivatives for treating neurodegenerative diseases
US20090281075A1 (en) * 2006-02-17 2009-11-12 Pharmacopeia, Inc. Isomeric purinones and 1h-imidazopyridinones as pkc-theta inhibitors
US7989459B2 (en) * 2006-02-17 2011-08-02 Pharmacopeia, Llc Purinones and 1H-imidazopyridinones as PKC-theta inhibitors
JP2009529541A (ja) * 2006-03-09 2009-08-20 ファーマコピア インコーポレーテッド 代謝性障害治療のための８−ヘテロアリ−ルプリンのｍｎｋ２阻害剤
WO2008043031A1 (en) * 2006-10-04 2008-04-10 Pharmacopeia, Inc. 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
AR063141A1 (es) * 2006-10-04 2008-12-30 Pharmacopeia Inc Derivados de 2- ( benzimidazolil ) purina 8- sustituida para inmunosupresion
US7902187B2 (en) * 2006-10-04 2011-03-08 Wyeth Llc 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
EP2078016B1 (en) 2006-10-19 2012-02-01 Signal Pharmaceuticals LLC Heteroaryl compounds, compositions thereof, and methods of treatment therewith
US20080119496A1 (en) * 2006-11-16 2008-05-22 Pharmacopeia Drug Discovery, Inc. 7-Substituted Purine Derivatives for Immunosuppression
JP2009007273A (ja) * 2007-06-27 2009-01-15 Ajinomoto Co Inc ジアミノピリミジン化合物の製造方法
US8110578B2 (en) 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
US8473571B2 (en) 2009-01-08 2013-06-25 Microsoft Corporation Synchronizing presentation states between multiple applications
KR101820541B1 (ko) * 2009-09-09 2018-02-28 다이닛본 스미토모 세이야꾸 가부시끼가이샤 8-옥소디히드로퓨린 유도체
ES2751705T3 (es) 2009-10-26 2020-04-01 Signal Pharm Llc Métodos de síntesis y purificación de compuestos heteroarilo
JP2014076947A (ja) * 2011-02-03 2014-05-01 Dainippon Sumitomo Pharma Co Ltd ２−オキシ置換８−オキソジヒドロプリン誘導体
EP2718464A1 (en) 2011-06-06 2014-04-16 Imperial Innovations Limited Methods to predict binding affinity of tspo imaging agents to tspo
MX384385B (es) 2011-10-19 2025-03-14 Signal Pharm Llc Tratamiento del cancer con inhibidores de tor cinasa
JP6076370B2 (ja) 2011-12-02 2017-02-08 シグナル ファーマシューティカルズ，エルエルシー ７−（６−（２−ヒドロキシプロパン−２−イル）ピリジン−３−イル）−１−（（トランス）−４−メトキシシクロヘキシル）−３，４−ジヒドロピラジノ［２，３−ｂ］ピラジン−２（１Ｈ）−オンの薬剤組成物、その固体形態、およびその使用方法
US9375443B2 (en) 2012-02-24 2016-06-28 Signal Pharmaceuticals, Llc Method for treating advanced non-small cell lung cancer (NSCLC) by administering a combination of a TOR kinase inhibitor and azacitidine or erlotinib
CN102675315B (zh) * 2012-02-28 2015-04-01 中国人民解放军第四军医大学 含取代苯烷基的嘌呤类化合物和制备方法及应用
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
AR094494A1 (es) 2013-01-16 2015-08-05 Signal Pharm Llc Pirrolopirimidinas sustituidas, sus composiciones, y sus métodos de tratamiento
US9782427B2 (en) 2013-04-17 2017-10-10 Signal Pharmaceuticals, Llc Methods for treating cancer using TOR kinase inhibitor combination therapy
WO2014172431A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer
EP2986319A1 (en) 2013-04-17 2016-02-24 Signal Pharmaceuticals, LLC Combination therapy comprising a tor kinase inhibitor and n-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide for treating cancer
HK1221150A1 (zh) 2013-04-17 2017-05-26 西格诺药品有限公司 用二氢吡嗪并-吡嗪类对癌症的治疗
JP6382949B2 (ja) 2013-04-17 2018-08-29 シグナル ファーマシューティカルズ，エルエルシー 癌を治療するためのｔｏｒキナーゼ阻害剤及び５−置換キナゾリノン化合物を含む組合せ療法
SG11201508223YA (en) 2013-04-17 2015-11-27 Signal Pharm Llc Treatment of cancer with dihydropyrazino-pyrazines
EP3549940A1 (en) 2013-04-17 2019-10-09 Signal Pharmaceuticals, LLC Pharmaceutical formulations, of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl) pyridin-3-yl) -3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one
US9604939B2 (en) 2013-05-29 2017-03-28 Signal Pharmaceuticals, Llc Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-YL)pyridin-3-YL)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-B]pyrazin-2(1H)-one, a solid form thereof and methods of their use
US9718824B2 (en) 2014-04-16 2017-08-01 Signal Pharmaceuticals, Llc Solid forms comprising 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one, and a coformer, compositions and methods of use thereof
JP2017511367A (ja) 2014-04-16 2017-04-20 シグナル ファーマシューティカルズ，エルエルシー １−エチル−７−（２−メチル−６−（１Ｈ−１，２，４−トリアゾール−３−イル）ピリジン−３−イル）−３，４−ジヒドロピラジノ［２，３−ｂ］ピラジン−２（１Ｈ）−オン及び共形成物を含む固体形態、その組成物及び使用方法
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
ES2823756T3 (es) 2014-04-16 2021-05-10 Signal Pharm Llc Métodos para tratar el cáncer usando terapia de combinación de inhibidores de quinasa TOR
CN106715427A (zh) 2014-07-14 2017-05-24 西格诺药品有限公司 利用取代的吡咯并嘧啶化合物、其组合物治疗癌症的方法
NZ629796A (en) 2014-07-14 2015-12-24 Signal Pharm Llc Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use
KR102708936B1 (ko) 2015-11-20 2024-09-25 포르마 세라퓨틱스 인크. 유비퀴틴-특이적 프로테아제 1 억제제로서의 퓨리논
MY198676A (en) 2017-06-22 2023-09-15 Celgene Corp Treatment of hepatocellular carcinoma characterized by hepatitis b virus infection
CN111699187A (zh) 2018-02-12 2020-09-22 豪夫迈·罗氏有限公司 用于治疗和预防病毒感染的新的砜化合物和衍生物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2525595A1 (fr) 1982-04-27 1983-10-28 Pharmuka Lab Nouveaux derives d'arene et d'heteroarenecarboxamides et leur utilisation comme medicaments
NL8202626A (nl) * 1982-06-29 1984-01-16 Stichting Rega V Z W Derivaten van 9-(2-hydroxyethoxymethyl)guanine.
FR2582514B1 (fr) 1985-05-30 1988-02-19 Rhone Poulenc Sante Medicaments a base d'amides, nouveaux amides et leur preparation
DK273689A (da) 1988-06-06 1989-12-07 Sanofi Sa 4-amino-3-carboxyquinoliner og -naphthyridiner, fremgangsmaade til deres fremstilling og anvendelse deraf i laegemidler
FR2632639B1 (fr) 1988-06-09 1990-10-05 Sanofi Sa Derives d'amino-4 carboxy-3 naphtyridines, leur preparation et compositions pharmaceutiques qui les contiennent
US6083953A (en) 1994-07-28 2000-07-04 Syntex (U.S.A.) Inc. 2- (2-amino-1,6-dihydro-6-oxo-purin-9-yl) methoxy-1,3- propanediol derivative
IL117659A (en) 1995-04-13 2000-12-06 Dainippon Pharmaceutical Co Substituted 2-phenyl pyrimidino amino acetamide derivative process for preparing the same and a pharmaceutical composition containing same
JP4667543B2 (ja) * 1996-07-03 2011-04-13 大日本住友製薬株式会社 新規プリン誘導体
US6211195B1 (en) * 1997-04-22 2001-04-03 Neurocrine Biosciences, Inc. CRF antagonistic thiophenopyridines
JP3814125B2 (ja) * 1999-06-02 2006-08-23 大日本住友製薬株式会社 ２−アリール−８−オキソジヒドロプリン誘導体からなる医薬

Also Published As

Publication number Publication date
NO20002835D0 (no) 2000-06-02
ZA9810490B (en) 1999-05-20
WO1999028320A1 (en) 1999-06-10
AR017796A1 (es) 2001-10-24
SK285703B6 (sk) 2007-06-07
AU744014B2 (en) 2002-02-14
DE69817611D1 (de) 2003-10-02
JP3815966B2 (ja) 2006-08-30
HUP0004422A3 (en) 2001-10-29
NO20002835L (no) 2000-07-24
CA2312885C (en) 2008-01-29
DE69817611T2 (de) 2004-02-26
RU2223272C2 (ru) 2004-02-10
TW502034B (en) 2002-09-11
EP1036794A4 (en) 2001-12-12
KR100494347B1 (ko) 2005-06-13
EP1036794A1 (en) 2000-09-20
ATE248169T1 (de) 2003-09-15
BR9815140A (pt) 2000-10-10
HK1028769A1 (en) 2001-03-02
HUP0004422A2 (hu) 2001-04-28
PL191489B1 (pl) 2006-05-31
EP1036794B1 (en) 2003-08-27
DK1036794T3 (da) 2003-12-22
TR200001600T2 (tr) 2000-11-21
PL340925A1 (en) 2001-03-12
CN1146566C (zh) 2004-04-21
AU1260499A (en) 1999-06-16
KR20010032686A (ko) 2001-04-25
ES2205574T3 (es) 2004-05-01
CN1284076A (zh) 2001-02-14
SK7972000A3 (en) 2001-03-12
CA2312885A1 (en) 1999-06-10
NZ504457A (en) 2001-12-21
IL135920A0 (en) 2001-05-20
PT1036794E (pt) 2003-11-28
US6372740B1 (en) 2002-04-16

Similar Documents

Publication Publication Date Title
ID24929A (id) Turunan 2-aril-8-oksodihidropurin, proses pembuatannya, komposisi farmasinya yang mengandungnya, dan senyawa antaranya
ID30299A (id) Turunan oksazolidinon, proses pembuatannya dan komposisi farmasi yang mengandungnya
ID25528A (id) Karboksamidotiazol tersubstitusi, pembuatannya dan komposisi farmasi yang mengandungnya
ID17307A (id) Komposisi oral dan proses pembuatannya.
ID16128A (id) Turunan arilglisinamida baru, proses pembuatannya dan komposisi-komposisi farmasi yang mengandung senyawa ini
ID26399A (id) Turunan 1-(1-tersubstitusi-4-piperidinil) metil -4-piperidin, proses pembuatannya, komposisi farmasi yang mengandung senyawa tersebut, dan intermedietnya
ID18046A (id) Senyawa siklik campuran, pembuatan dan penngunaannya.
ID26589A (id) 4-haloalkil -3-heterosiklilpiridina dan 4- haloalkil-5-heterosiklilpirimidina proses untuk pembuatannya komposisi yang terdiri darinya dan pemakaiannya sebagai pestisida
ID21045A (id) Asam amino termodifikasi, obat-obatan yang mengandung senyawa ini dan proses pembuatannya
ID28728A (id) Komposisi dan proses pengkrepan
ID15947A (id) Senyawa fenol dan proses pembuatannya
ID22528A (id) Komposisi farmasi fenofibrat yang memiliki biovabilitas tinggi dan metoda pembuatannya
ID22821A (id) Turunan sulfonamida, proses pembuatannya dan penggunaannya sebagai obat
ID19290A (id) Turunan-turunan propiofenon dan proses pembuatannya
ID26172A (id) Proses pembuatan surfaktan-surfaktan alkilbenzenasulfonat dan produk-produknya
ID27680A (id) Komposisi poliester, metoda produksi daripadanya dan film poliester
ID20604A (id) Polisakarida sintetis proses untuk pembuatan dan komposisi farmasi yang dikandungnya
ID25469A (id) Komposisi sefalosporin amorf yang stabil secara kristalografi dan proses pembuatannya
ID20137A (id) Turunan propanolamina, proses pembuatannya, sediaan farmasi yang mengandung senyawa ini, dan penggunannya
ID17810A (id) Turunan-turunan 2,4-tiazolidindion tersubstitusi baru, proses untuk pembuatannya dan komposisi farmasi yang mengandungnya
ID29295A (id) Senyawa pirimidinona, komposisi farmasi yang mengandung senyawa tersebut dan proses penyediaannya senyawa tersebut
ID23436A (id) Senyawa-senyawa akrilonitril, proses untuk produksinya dan pestisida-pestisida yang mengandungnya
ID22911A (id) Turunan-turunan triazol baru, proses pembuatan dan komposisi-komposisi farmasi yang mengandungnya
ID24070A (id) Katalis yang mengandung hologen dan proses pembuatannya
ID22572A (id) Proses yang disempurnakan untuk pembuatan 3,5,5-trimetilsikloheksa-3-en-1-on (betha-isoforon) dengan isomerisasi 3,5,5-trimetilsikloheksa-2-en-1-on (alpha-isoforon) (ii)